{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T22:31:32Z","timestamp":1781044292899,"version":"3.54.1"},"reference-count":11,"publisher":"American Medical Association (AMA)","issue":"12","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Oncol"],"DOI":"10.1001\/jamaoncol.2018.3486","type":"journal-article","created":{"date-parts":[[2018,9,3]],"date-time":"2018-09-03T18:36:07Z","timestamp":1535999767000},"page":"e183486","source":"Crossref","is-referenced-by-count":28,"title":["Safety and Efficacy of Bevacizumab Plus Standard-of-Care Treatment Beyond Disease Progression in Patients With Advanced Non\u2013Small Cell Lung Cancer"],"prefix":"10.1001","volume":"4","author":[{"given":"Cesare","family":"Gridelli","sequence":"first","affiliation":[{"name":"Division of Medical Oncology, S.G. Moscati Hospital, Avellino, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javier","family":"de Castro Carpeno","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology, Hospital Universitario La Paz, IdiPAZ, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne-Marie C.","family":"Dingemans","sequence":"additional","affiliation":[{"name":"Department of Pulmonology, Maastricht University Medical Center, Maastricht, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank","family":"Griesinger","sequence":"additional","affiliation":[{"name":"Department of Hematology and Oncology, University Department of Internal Medicine\u2013Oncology, Pius-Hospital, University of Oldenburg, Oldenburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Grossi","sequence":"additional","affiliation":[{"name":"Lung Cancer Unit, Ospedale Policlinico San Martino, Genova, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Corey","family":"Langer","sequence":"additional","affiliation":[{"name":"Thoracic Oncology Unit, Abramson Cancer Center, University of Pennsylvania, Philadelphia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuichiro","family":"Ohe","sequence":"additional","affiliation":[{"name":"Department of Thoracic Oncology, National Cancer Center Hospital, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Konstantinos","family":"Syrigos","sequence":"additional","affiliation":[{"name":"Department of Medicine, National and Kapodistrian University, Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nick","family":"Thatcher","sequence":"additional","affiliation":[{"name":"Christie Hospital NHS Trust, Manchester, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashis","family":"Das-Gupta","sequence":"additional","affiliation":[{"name":"F. Hoffmann-La Roche Ltd, Basel, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matt","family":"Truman","sequence":"additional","affiliation":[{"name":"Roche Products Pty Ltd, Sydney, New South Wales, Australia"},{"name":"Now with OzBiostat Pty Ltd, Manly, New South Wales, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margarita","family":"Donica","sequence":"additional","affiliation":[{"name":"F. Hoffmann-La Roche Ltd, Basel, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vlatka","family":"Smoljanovic","sequence":"additional","affiliation":[{"name":"F. Hoffmann-La Roche Ltd, Basel, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaafar","family":"Bennouna","sequence":"additional","affiliation":[{"name":"Institut de Canc\u00e9rologie de l\u2019Ouest, Nantes, France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","published-online":{"date-parts":[[2018,12,13]]},"reference":[{"issue":"4","key":"cbr180013r1","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1007\/s11523-014-0355-4","article-title":"Effectiveness and safety of post-induction phase bevacizumab treatment for patients with non-small-cell lung cancer: results from the ARIES observational cohort study.","volume":"10","author":"Kosty","year":"2015","journal-title":"Target Oncol"},{"issue":"4","key":"cbr180013r2","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1634\/theoncologist.2010-0287","article-title":"Bevacizumab treatment to progression after chemotherapy: outcomes from a US community practice network.","volume":"16","author":"Nadler","year":"2011","journal-title":"Oncologist"},{"issue":"7","key":"cbr180013r3","doi-asserted-by":"publisher","first-page":"1050","DOI":"10.1002\/cncr.v122.7","article-title":"Bevacizumab beyond disease progression after first-line treatment with bevacizumab plus chemotherapy in advanced nonsquamous non-small cell lung cancer (West Japan Oncology Group 5910L): an open-label, randomized, phase 2 trial.","volume":"122","author":"Takeda","year":"2016","journal-title":"Cancer"},{"issue":"7","key":"cbr180013r4","doi-asserted-by":"publisher","first-page":"726","DOI":"10.1002\/pds.v23.7","article-title":"Bevacizumab exposure beyond first disease progression in patients with metastatic colorectal cancer: analyses of the ARIES observational cohort study.","volume":"23","author":"Grothey","year":"2014","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"1","key":"cbr180013r5","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/S1470-2045(12)70477-1","article-title":"Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): a randomised phase 3 trial.","volume":"14","author":"Bennouna","year":"2013","journal-title":"Lancet Oncol"},{"issue":"11","key":"cbr180013r6","doi-asserted-by":"publisher","first-page":"1269","DOI":"10.1016\/S1470-2045(14)70439-5","article-title":"Bevacizumab plus chemotherapy versus chemotherapy alone as second-line treatment for patients with HER2-negative locally recurrent or metastatic breast cancer after first-line treatment with bevacizumab plus chemotherapy (TANIA): an open-label, randomised phase 3 trial.","volume":"15","author":"von Minckwitz","year":"2014","journal-title":"Lancet Oncol"},{"key":"cbr180013r7","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.lungcan.2016.07.015","article-title":"Somatic alterations in lung cancer: do environmental factors matter?","volume":"100","author":"Gibelin","year":"2016","journal-title":"Lung Cancer"},{"issue":"2","key":"cbr180013r8","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1016\/j.ejcsup.2013.07.004","article-title":"Molecular profile of lung cancer in never smokers.","volume":"11","author":"Subramanian","year":"2013","journal-title":"EJC Suppl"},{"issue":"10","key":"cbr180013r9","doi-asserted-by":"publisher","first-page":"963","DOI":"10.1002\/phar.2015.35.issue-10","article-title":"Immune checkpoint inhibitors: new insights and current place in cancer therapy.","volume":"35","author":"La-Beck","year":"2015","journal-title":"Pharmacotherapy"},{"key":"cbr180013r10","unstructured":"Tarceva (erlotinib) [package insert]. Melville, NY: OSI Pharmaceuticals; 2004. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2004\/021743lbl.pdf. Accessed January 1, 2018."},{"key":"cbr180013r11","unstructured":"Erlotinib summary of product characteristics. European Medicines Agency. http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/000618\/WC500033994.pdf. Accessed January 1, 2018."}],"container-title":["JAMA Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamaoncology\/fullarticle\/2698039","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2018,12,13]],"date-time":"2018-12-13T12:13:08Z","timestamp":1544703188000},"score":1,"resource":{"primary":{"URL":"http:\/\/oncology.jamanetwork.com\/article.aspx?doi=10.1001\/jamaoncol.2018.3486"}},"subtitle":["The AvaALL Randomized Clinical Trial"],"short-title":[],"issued":{"date-parts":[[2018,12,13]]},"references-count":11,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2018,12,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamaoncol.2018.3486","relation":{},"ISSN":["2374-2437"],"issn-type":[{"value":"2374-2437","type":"print"}],"subject":[],"published":{"date-parts":[[2018,12,13]]}}}